Temporal trends in the use of drug-eluting stents for approved and off-label indications: A longitudinal analysis of a large multicenter percutaneous coronary intervention registry

Clinical Cardiology

Volumn 33, Issue 2, 2010, Pages 111-116

  Gualano, Sarah K ^a   Gurm, Hitinder S ^a   Share, David ^a   Smith, Dean ^a   Aronow, Herbert D ^b   Lalonde, Thomas ^c   Bates, Eric R ^a   Changezi, Hameem ^d   McNamara, Richard ^e   Moscucci, Mauro ^a,f  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b ST JOSEPH MERCY HOSPITAL   (United States)

^c ST JOHN HOSPITAL AND MEDICAL CENTER   (United States)

^d GENESYS REGIONAL MEDICAL CENTER   (United States)

^e SPECTRUM HEALTH   (United States)

^f UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGED; ARTICLE; BARE METAL STENT; CONTROLLED STUDY; DRUG ELUTING STENT; FEMALE; HUMAN; IN-STENT RESTENOSIS; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS CORONARY INTERVENTION; SAPHENOUS VEIN GRAFT; ST SEGMENT ELEVATION; STENT THROMBOSIS; SURGICAL TECHNIQUE; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT INDICATION; TREND STUDY;

AGED; AGED, 80 AND OVER; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; DRUG-ELUTING STENTS; FEMALE; GUIDELINE ADHERENCE; HEART DISEASES; HUMANS; LONGITUDINAL STUDIES; MALE; METALS; OFF-LABEL USE; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES AS TOPIC; PRODUCT LABELING; PROSTHESIS DESIGN; REGISTRIES; STENTS; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES;

EID: 77649267515     PISSN: 01609289     EISSN: 19328737     Source Type: Journal    
DOI: 10.1002/clc.20717     Document Type: Article

References (18)

1. Abbott JD, Voss MR, Nakamura M, et al. Unrestricted use of drug-eluting stents compared with bare-metal stents in routine clinical practice. J Am Coll Cardiol. 2007;50:2029-2036.
2. Nordmann AJ, Briel M, Bucher HC. Mortality in randomized controlled trials comparing drug-eluting vs bare-metal stents in coronary artery disease: a meta-analysis. Eur Heart J. 2006;24:2737-2739.
3. Pfisterer M, Brunner-La Rocca HP, Buser PT, et al. Late clinical events after clopidogrel discontinuation may limit benefit of drug-eluting stents: an observational study of drug-eluting vs bare metal stents. J Am Coll Cardiol. 2006;48:2584-2591.
4. Lagerqvist B, James SK, Stenestrand U, et al. Long-term outcomes with drug-eluting stents vs bare metal stents in Sweden. N Eng J Med. 2007;356:1009-1019.
5. Farb A, Boam AB. Stent thrombosis redux-the FDA perspective. N Engl J Med. 2007;356:984-987.
6. Kline-Rogers E, Share D, Bondie D, et al. Development of a multicenter interventional cardiology database: the Blue Cross Blue Shield of Michigan Cardiovascular Consortium (BMC2) experience. J Interv Cardiol. 2002;15:387-392.
7. Moscucci M, Kline-Rogers E, Share D, et al. Simple bedside additive tool for prediction of in-hospital mortality after percutaneous coronary interventions. Circulation. 2001;104:263-268.
8. Moscucci M, Eagle KA, Share D, et al. Public reporting and case selection for percutaneous coronary interventions: an analysis from two large multicenter percutaneous coronary intervention databases. J Am Coll Card. 2005;45:1759-1765.
9. Moscucci M, Rogers EK, Montoye C, et al. Association of a continuous quality improvement initiative with practice and outcome variations of a contemporary percutaneous coronary interventions. Circulation. 2006;113:814-822.
10. Grines CL, Bonow RO, Casey DE Jr, et al. Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents. J Am Coll Cardiol. 2007;49:734-739.
11. Tu JV, Bowen J, Chiu M, et al. Effectiveness and safety of drug-eluting stents in Ontario. N Engl J Med. 2007;357:1393-1402.
12. James SK, Stenestrandn U, Lindback J, et al. Long-term safety and efficacy of drug-eluting stents in Sweden. N Eng J Med. 2009;360:1933-1945.
13. Stone GW, Lansky AJ, Pocock SJ, et al. Paclitaxel-eluting stents vs bare-metal stents in acute myocardial infarction. N Eng J Med. 2009;360:1946-1959.
14. Kastrati A, Mehilli J, von Beckerath N, et al. Sirolimus-eluting stent or paclitaxel-eluting stent vs balloon angioplasty for prevention of recurrences in patients with coronary in-stent restenosis. JAMA. 2005;293:165-171.
15. Dibra A, Kastrati A, Wehilli J, et al. Paclitaxel-eluting or sirolimus-eluting stents to prevent restenosis in diabetic patients. N Engl J Med. 2005;353:663-670.
16. Boyden TF, Nallamothu BK, Moscucci M, et al. Meta-analysis of randomized trials of drug-eluting stents vs bare metal stents in patients with diabetes mellitus. Am J Cardiol. 2007;99(10):1399-1402.
17. Khanderia U, Townsend KA, Eagle K, et al. Statin initiation following coronary artery bypass grafting. Chest. 2005;127:455-463.
18. Roe MT, Chen AY, Cannon CP, et al. Temproal changes in the use of drug-eluting stents for patients with non-ST-segment-elevation myocardial infarction undergoing percutaneous coronary intervention. Circ Cardiovasc Qual Outcomes. 2009.